HAIKOU CITY, China, April 15,
2020 /PRNewswire/ -- China Pharmaceutical Holdings Limited
(NYSE American: CPHI) ("China Pharma" or "Company"), an NYSE
American-listed corporation with a fully-integrated specialty
pharmaceuticals subsidiary based in China, today announced that its subsidiary,
Hainan Helpson Pharmaceutical & Biotechnology Co., Ltd.
("Helpson") launched mask production lines.
The masks are produced in Class 100,000 Clean Room (air
cleanliness class refers to the classification criteria for
classification by maximum concentration limits of particles that
are greater than or equal to the particle sizes under consideration
in the Clean Room) by our subsidiary, Helpson, a cGMP certified
pharmaceutical manufacturer, which
ensures safety and health.
Ms. Li Zhilin, President and CEO
of China Pharmaceutical said, "On the one hand, although the
COVID-19 outbreak has been controlled to a certain extent in
China currently; the government
and the public's awareness of epidemic prevention is still strong.
And activities such as work resumption and schools re-open create a
high demand for protective masks. On the other hand, the global
outbreak of COVID-19 has led to a surge in demand for protective
equipment such as masks. In this circumstance, we take the time to
launch mask production lines, adhering to our corporate mission of
providing basic medical protection measures to the general public,
and fulfilling our social responsibility with practical actions.
"
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical
company that develops, manufactures and markets a diversified
portfolio of products, focusing on conditions with high incidence
and high mortality rates in China,
including cardiovascular, CNS, infectious, and digestive diseases.
The Company's cost-effective business model is driven by market
demand and supported by new GMP-certified product lines covering
the major dosage forms. In addition, the Company has a broad and
expanding nationwide distribution network across all major cities
and provinces in China. The
Company's wholly-owned subsidiary, Hainan Helpson Medical &
Biotechnology Co., Ltd., is located in Haikou City, Hainan
Province. For more information about China Pharma Holdings,
Inc., please visit www.chinapharmaholdings.com. The Company
routinely posts important information on its website.
Safe Harbor Statement
Certain statements in this press release constitute
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Any statements set forth above that are not historical facts
are forward-looking statements that involve risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements. Such risks and uncertainties may
include, but are not limited to: the achievability of financial
guidance; success of new product development; unanticipated changes
in product demand; increased competition; downturns in the Chinese
economy; uncompetitive levels of research and development; and
other information detailed from time to time in the Company's
filings and future filings with the United States Securities and
Exchange Commission. The forward-looking statements made herein
speak only as of the date of this press release and the Company
undertakes no duty to update any forward-looking statement to
conform the statement to actual results or changes in the Company's
expectations, except as required by applicable law or
regulations.
View original
content:http://www.prnewswire.com/news-releases/china-pharmaceutical-holdings-co-ltd-added-mask-production-lines-301040765.html
SOURCE China Pharma Holdings, Inc.